300254.SZ
Shanxi C&Y Pharmaceutical Group Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 7.86
+2.34%Year over year
Reported trailing growth
- Revenue
- +2.9%
- EBITDA
- —
- EBIT
- +6.5%
- EPS
- -48.8%
- Free cash flow
- +984.7%
- Operating cash flow
- +177.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.7%
- EBITDA
- +19.5%
- EBIT
- +41.0%
- Net income
- -0.7%
- EPS
- -0.9%
- Free cash flow
- +9.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026